Ionis Pharmaceuticals, Inc. (IONS)
USD 25.98
(-4.1%)
USD 25.98
(-4.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 779.58 Million USD | 15.06% |
| 2022 | 984 Million USD | 18.7% |
| 2021 | 829 Million USD | -6.75% |
| 2020 | 889 Million USD | 18.06% |
| 2019 | 753 Million USD | 14.22% |
| 2018 | 659.22 Million USD | 36.45% |
| 2017 | 483.13 Million USD | 22.95% |
| 2016 | 392.93 Million USD | 9.31% |
| 2015 | 359.46 Million USD | 37.26% |
| 2014 | 261.89 Million USD | 31.64% |
| 2013 | 198.95 Million USD | 16.36% |
| 2012 | 170.97 Million USD | 0.46% |
| 2011 | 170.18 Million USD | 8.52% |
| 2010 | 156.82 Million USD | 5.16% |
| 2009 | 149.13 Million USD | 24.02% |
| 2008 | 120.25 Million USD | 10.76% |
| 2007 | 108.56 Million USD | 16.51% |
| 2006 | 93.18 Million USD | 3.13% |
| 2005 | 90.35 Million USD | -29.44% |
| 2004 | 128.05 Million USD | 0.7% |
| 2003 | 127.16 Million USD | -1.89% |
| 2002 | 129.61 Million USD | 30.43% |
| 2001 | 99.37 Million USD | 38.44% |
| 2000 | 71.78 Million USD | -12.68% |
| 1999 | 82.2 Million USD | 8.16% |
| 1998 | 76 Million USD | 13.1% |
| 1997 | 67.2 Million USD | 23.3% |
| 1996 | 54.5 Million USD | 31.64% |
| 1995 | 41.4 Million USD | 13.74% |
| 1994 | 36.4 Million USD | 355.0% |
| 1993 | 8 Million USD | -75.23% |
| 1992 | 32.3 Million USD | 509.43% |
| 1991 | 5.3 Million USD | 152.38% |
| 1990 | 2.1 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 281.59 Million USD | 7.81% |
| 2024 Q1 | 261.2 Million USD | -20.26% |
| 2023 Q2 | 276 Million USD | 13.11% |
| 2023 Q4 | 327.55 Million USD | 14.93% |
| 2023 Q3 | 285 Million USD | 3.26% |
| 2023 Q1 | 244 Million USD | -31.46% |
| 2023 FY | 1.13 Billion USD | 15.06% |
| 2022 Q4 | 356 Million USD | 63.76% |
| 2022 Q3 | 217.39 Million USD | 1.32% |
| 2022 Q1 | 195.22 Million USD | -10.03% |
| 2022 Q2 | 214.55 Million USD | 9.9% |
| 2022 FY | 984 Million USD | 18.7% |
| 2021 Q3 | 214.87 Million USD | 16.52% |
| 2021 Q4 | 217 Million USD | 0.99% |
| 2021 Q1 | 196.9 Million USD | -36.48% |
| 2021 Q2 | 184.4 Million USD | -6.35% |
| 2021 FY | 829 Million USD | -6.75% |
| 2020 Q1 | 191.94 Million USD | -17.26% |
| 2020 Q2 | 194.27 Million USD | 1.22% |
| 2020 Q3 | 193.53 Million USD | -0.39% |
| 2020 FY | 889 Million USD | 18.06% |
| 2020 Q4 | 310 Million USD | 60.18% |
| 2019 Q3 | 164.4 Million USD | -9.67% |
| 2019 Q4 | 232 Million USD | 41.12% |
| 2019 Q1 | 174.63 Million USD | -3.28% |
| 2019 FY | 753 Million USD | 14.22% |
| 2019 Q2 | 182 Million USD | 4.22% |
| 2018 Q1 | 147.72 Million USD | -15.1% |
| 2018 Q3 | 163.96 Million USD | -2.42% |
| 2018 Q4 | 180.55 Million USD | 10.12% |
| 2018 Q2 | 168.02 Million USD | 13.75% |
| 2018 FY | 659.22 Million USD | 36.45% |
| 2017 Q4 | 173.99 Million USD | 62.61% |
| 2017 Q2 | 105.82 Million USD | 9.87% |
| 2017 Q1 | 96.31 Million USD | -19.19% |
| 2017 FY | 483.13 Million USD | 22.95% |
| 2017 Q3 | 107 Million USD | 1.11% |
| 2016 Q3 | 94.81 Million USD | 8.49% |
| 2016 Q4 | 119.19 Million USD | 25.71% |
| 2016 FY | 392.93 Million USD | 9.31% |
| 2016 Q1 | 91.52 Million USD | -20.07% |
| 2016 Q2 | 87.39 Million USD | -4.51% |
| 2015 Q3 | 97.25 Million USD | 28.34% |
| 2015 FY | 359.46 Million USD | 37.26% |
| 2015 Q1 | 71.91 Million USD | -3.84% |
| 2015 Q4 | 114.51 Million USD | 17.74% |
| 2015 Q2 | 75.78 Million USD | 5.38% |
| 2014 FY | 261.89 Million USD | 31.64% |
| 2014 Q3 | 65.55 Million USD | 2.87% |
| 2014 Q4 | 74.78 Million USD | 14.07% |
| 2014 Q2 | 63.72 Million USD | 10.2% |
| 2014 Q1 | 57.82 Million USD | -6.89% |
| 2013 Q2 | 46.02 Million USD | 10.27% |
| 2013 Q1 | 41.73 Million USD | -9.26% |
| 2013 FY | 198.95 Million USD | 16.36% |
| 2013 Q4 | 62.1 Million USD | 26.51% |
| 2013 Q3 | 49.09 Million USD | 6.67% |
| 2012 Q2 | 43.64 Million USD | 4.69% |
| 2012 Q1 | 41.69 Million USD | -18.29% |
| 2012 Q3 | 39.64 Million USD | -9.16% |
| 2012 Q4 | 45.99 Million USD | 16.0% |
| 2012 FY | 170.97 Million USD | 0.46% |
| 2011 Q2 | 38.88 Million USD | 4.37% |
| 2011 Q3 | 43.02 Million USD | 10.66% |
| 2011 FY | 170.18 Million USD | 8.52% |
| 2011 Q4 | 51.01 Million USD | 18.57% |
| 2011 Q1 | 37.25 Million USD | -11.88% |
| 2010 Q1 | 34.8 Million USD | -20.77% |
| 2010 FY | 156.82 Million USD | 5.16% |
| 2010 Q2 | 42.17 Million USD | 21.17% |
| 2010 Q3 | 37.57 Million USD | -10.92% |
| 2010 Q4 | 42.27 Million USD | 12.53% |
| 2009 Q3 | 37.16 Million USD | 3.76% |
| 2009 FY | 149.13 Million USD | 24.02% |
| 2009 Q4 | 43.93 Million USD | 18.2% |
| 2009 Q2 | 35.81 Million USD | 11.18% |
| 2009 Q1 | 32.21 Million USD | 84.81% |
| 2008 Q2 | 36.09 Million USD | 19.58% |
| 2008 Q1 | 30.18 Million USD | -9.0% |
| 2008 FY | 120.25 Million USD | 10.76% |
| 2008 Q3 | 36.53 Million USD | 1.23% |
| 2008 Q4 | 17.43 Million USD | -52.29% |
| 2007 Q2 | 23.47 Million USD | 0.52% |
| 2007 Q4 | 33.17 Million USD | 16.09% |
| 2007 Q3 | 28.57 Million USD | 21.73% |
| 2007 Q1 | 23.35 Million USD | -18.81% |
| 2007 FY | 108.56 Million USD | 16.51% |
| 2006 FY | 93.18 Million USD | 3.13% |
| 2006 Q4 | 28.76 Million USD | 31.95% |
| 2006 Q3 | 21.79 Million USD | 0.48% |
| 2006 Q2 | 21.69 Million USD | 3.6% |
| 2006 Q1 | 20.93 Million USD | -11.56% |
| 2005 Q1 | 23.86 Million USD | -22.41% |
| 2005 Q3 | 19.95 Million USD | -12.74% |
| 2005 Q2 | 22.86 Million USD | -4.19% |
| 2005 FY | 90.35 Million USD | -29.44% |
| 2005 Q4 | 23.67 Million USD | 18.66% |
| 2004 Q3 | 31.47 Million USD | 0.93% |
| 2004 Q1 | 34.63 Million USD | 11.09% |
| 2004 FY | 128.05 Million USD | 0.7% |
| 2004 Q2 | 31.18 Million USD | -9.97% |
| 2004 Q4 | 30.75 Million USD | -2.28% |
| 2003 Q3 | 30.36 Million USD | -7.25% |
| 2003 Q4 | 31.17 Million USD | 2.69% |
| 2003 Q2 | 32.73 Million USD | -0.48% |
| 2003 Q1 | 32.89 Million USD | 3.66% |
| 2003 FY | 127.16 Million USD | -1.89% |
| 2002 FY | 129.61 Million USD | 30.43% |
| 2002 Q1 | 27.67 Million USD | -5.99% |
| 2002 Q3 | 37.8 Million USD | 16.69% |
| 2002 Q4 | 31.73 Million USD | -16.07% |
| 2002 Q2 | 32.4 Million USD | 17.06% |
| 2001 Q3 | 24.01 Million USD | -0.19% |
| 2001 FY | 99.37 Million USD | 38.44% |
| 2001 Q4 | 29.44 Million USD | 22.61% |
| 2001 Q2 | 24.05 Million USD | 10.01% |
| 2001 Q1 | 21.86 Million USD | -6.88% |
| 2000 Q3 | 18.07 Million USD | 19.22% |
| 2000 Q1 | 15.06 Million USD | -44.62% |
| 2000 Q2 | 15.16 Million USD | 0.64% |
| 2000 FY | 71.78 Million USD | -12.68% |
| 2000 Q4 | 23.48 Million USD | 29.93% |
| 1999 Q4 | 27.2 Million USD | 45.45% |
| 1999 Q3 | 18.7 Million USD | -2.6% |
| 1999 Q2 | 19.2 Million USD | 12.28% |
| 1999 FY | 82.2 Million USD | 8.16% |
| 1999 Q1 | 17.1 Million USD | -21.2% |
| 1998 Q2 | 18.8 Million USD | 11.9% |
| 1998 FY | 76 Million USD | 13.1% |
| 1998 Q4 | 21.7 Million USD | 15.43% |
| 1998 Q3 | 18.8 Million USD | 0.0% |
| 1998 Q1 | 16.8 Million USD | -27.27% |
| 1997 Q3 | 15.2 Million USD | -1.94% |
| 1997 FY | 67.2 Million USD | 23.3% |
| 1997 Q1 | 13.5 Million USD | -27.81% |
| 1997 Q2 | 15.5 Million USD | 14.81% |
| 1997 Q4 | 23.1 Million USD | 51.97% |
| 1996 FY | 54.5 Million USD | 31.64% |
| 1996 Q4 | 18.7 Million USD | 58.47% |
| 1996 Q3 | 11.8 Million USD | -7.81% |
| 1996 Q2 | 12.8 Million USD | 14.29% |
| 1996 Q1 | 11.2 Million USD | -9.68% |
| 1995 Q1 | 8.7 Million USD | -33.08% |
| 1995 Q4 | 12.4 Million USD | 11.71% |
| 1995 Q2 | 9.3 Million USD | 6.9% |
| 1995 Q3 | 11.1 Million USD | 19.35% |
| 1995 FY | 41.4 Million USD | 13.74% |
| 1994 FY | 36.4 Million USD | 355.0% |
| 1994 Q4 | 13 Million USD | 58.54% |
| 1994 Q2 | 7.9 Million USD | 11.27% |
| 1994 Q1 | 7.1 Million USD | 147.02% |
| 1994 Q3 | 8.2 Million USD | 3.8% |
| 1993 Q4 | -15.1 Million USD | -296.1% |
| 1993 FY | 8 Million USD | -75.23% |
| 1993 Q1 | 7.8 Million USD | -70.23% |
| 1993 Q2 | 7.8 Million USD | 0.0% |
| 1993 Q3 | 7.7 Million USD | -1.28% |
| 1992 Q4 | 26.2 Million USD | 1278.95% |
| 1992 FY | 32.3 Million USD | 509.43% |
| 1992 Q2 | 1.9 Million USD | -5.0% |
| 1992 Q1 | 2 Million USD | 17.65% |
| 1992 Q3 | 1.9 Million USD | 0.0% |
| 1991 FY | 5.3 Million USD | 152.38% |
| 1991 Q3 | 1.2 Million USD | -70.0% |
| 1991 Q1 | 900 Thousand USD | 113.85% |
| 1991 Q2 | 4 Million USD | 344.44% |
| 1991 Q4 | 1.7 Million USD | 41.67% |
| 1990 Q2 | - USD | 0.0% |
| 1990 FY | 2.1 Million USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | -6.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -183.247% |
| Alkermes plc | 996.24 Million USD | 21.748% |
| Agenus Inc. | 78.18 Million USD | -897.131% |
| Aptorum Group Limited | 10.56 Thousand USD | -7378160.458% |
| Ardelyx, Inc. | 169.93 Million USD | -358.751% |
| Dyadic International, Inc. | 9.15 Million USD | -8417.567% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -3403.289% |
| Lantern Pharma Inc. | 17.87 Million USD | -4260.699% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -11480.414% |
| Novavax, Inc. | 779.12 Million USD | -0.059% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -861.717% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -848.449% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -3914.658% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -2533.206% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1367.42% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -104.887% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3107.305% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1958.642% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -2433.512% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -820.236% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4365.756% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -362.839% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2282.965% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -387.891% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 56.691% |
| AlloVir, Inc. | 180.93 Million USD | -330.871% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -74.898% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -2526.464% |
| Bicycle Therapeutics plc | 216.92 Million USD | -259.386% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -353.507% |
| ChromaDex Corporation | 56.37 Million USD | -1282.761% |
| Chimerix, Inc. | 93.38 Million USD | -734.774% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -5504.652% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -417.874% |
| CRISPR Therapeutics AG | 463.49 Million USD | -68.198% |
| Precision BioSciences, Inc. | 92.46 Million USD | -743.134% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -206.871% |
| Fortress Biotech, Inc. | 200.19 Million USD | -289.414% |
| Fortress Biotech, Inc. | 200.19 Million USD | -289.414% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2280.709% |
| ImmuCell Corporation | 9.61 Million USD | -8006.038% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -393.991% |
| Immix Biopharma, Inc. | 16.14 Million USD | -4729.822% |
| Incyte Corporation | 1.19 Billion USD | 34.516% |
| Innoviva, Inc. | 132.15 Million USD | -489.908% |
| IO Biotech, Inc. | 91.44 Million USD | -752.539% |
| Jaguar Health, Inc. | 42.01 Million USD | -1755.497% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -360.539% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -824.525% |
| ContextLogic Inc. | 387 Million USD | -101.444% |
| MiMedx Group, Inc. | 229.72 Million USD | -239.354% |
| MEI Pharma, Inc. | 34.78 Million USD | -2141.159% |
| NextCure, Inc. | 67.63 Million USD | -1052.604% |
| Onconetix, Inc. | 34.9 Million USD | -2133.298% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -6016.327% |
| Opthea Limited | 191.96 Million USD | -306.104% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -28232.288% |
| Vaxcyte, Inc. | 468.04 Million USD | -66.564% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1711.088% |
| Precigen, Inc. | 84.18 Million USD | -826.084% |
| Pharming Group N.V. | 225.49 Million USD | -245.729% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -364.518% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -974.314% |
| PureTech Health plc | 144.59 Million USD | -439.145% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -498.472% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -217.994% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3107.305% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -240.907% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -2426.287% |
| Acelyrin, Inc. | 422.06 Million USD | -84.708% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -6046022.227% |
| Summit Therapeutics Inc. | 87.68 Million USD | -789.067% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2003.354% |
| Senti Biosciences, Inc. | 94.7 Million USD | -723.174% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -530.974% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1615.452% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -2545.448% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -19676.192% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -489.814% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2187.185% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -9124.79% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -329.996% |
| Seer, Inc. | 110.49 Million USD | -605.572% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1004.325% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -733.979% |
| ESSA Pharma Inc. | 32.13 Million USD | -2326.042% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1884.425% |
| GT Biopharma, Inc. | 13.57 Million USD | -5642.391% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -254.632% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -287.632% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -200.506% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1273.504% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1341.544% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -7744.786% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -93.176% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -4018.48% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1437.859% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -200.235% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1389.012% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -5309.901% |
| Soligenix, Inc. | 7.79 Million USD | -9900.794% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1290.357% |
| Kura Oncology, Inc. | 165.8 Million USD | -370.186% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -580.82% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -9271.162% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -31314.198% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -623.864% |
| Autolus Therapeutics plc | 196.72 Million USD | -296.281% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -820.877% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -569.443% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -3922.014% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -142.29% |
| GRI Bio, Inc. | 11.33 Million USD | -6780.733% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -10949.037% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -494.229% |
| IGM Biosciences, Inc. | 265.59 Million USD | -193.529% |
| INmune Bio, Inc. | 29.89 Million USD | -2507.663% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -351.793% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1833.772% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4778.712% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -4852.415% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1155.414% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -625.049% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -182.774% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -158.612% |
| Verastem, Inc. | 92.08 Million USD | -746.604% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -4245.766% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -319.753% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -542.127% |
| Histogen Inc. | 14.27 Million USD | -5362.353% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -4757.802% |
| Surrozen, Inc. | 18.55 Million USD | -4102.625% |
| Organovo Holdings, Inc. | 14.91 Million USD | -5126.866% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15215.341% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1206.428% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -2939.681% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1558.484% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -10113.586% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -337.636% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1509.123% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -218.194% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -4973.265% |
| Apollomics, Inc. | 54.14 Million USD | -1339.946% |
| Amarin Corporation plc | 272.35 Million USD | -186.237% |
| Mesoblast Limited | 5.9 Million USD | -13108.861% |
| Turnstone Biologics Corp. | 78.33 Million USD | -895.158% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -219.343% |
| Synaptogenix, Inc. | 8.31 Million USD | -9276.963% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -5244.762% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -208.069% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2238.99% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -8727.61% |
| Exelixis, Inc. | 1.58 Billion USD | 50.87% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1937.497% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -235.956% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 8.842% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6502.717% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -9594.058% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -2499.23% |
| Gritstone bio, Inc. | 148.37 Million USD | -425.42% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1032.117% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -4665.138% |
| Avid Bioservices, Inc. | 25.99 Million USD | -2898.873% |
| Insmed Incorporated | 949.26 Million USD | 17.874% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -4868.754% |
| MediWound Ltd. | 18.86 Million USD | -4031.795% |
| OmniAb, Inc. | 83.89 Million USD | -829.241% |
| Alector, Inc. | 248.8 Million USD | -213.336% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -232.719% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1392.004% |
| Zai Lab Limited | 547.47 Million USD | -42.397% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -95.555% |
| Aura Biosciences, Inc. | 84.99 Million USD | -817.258% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -215.446% |
| Immunic, Inc. | 99.22 Million USD | -685.692% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -390.269% |
| Veracyte, Inc. | 357.93 Million USD | -117.802% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 91.353% |
| FibroGen, Inc. | 398.11 Million USD | -95.821% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5386.186% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -11218.133% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -10840.448% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 76.054% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -2913.13% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -146.282% |
| TG Therapeutics, Inc. | 198.47 Million USD | -292.789% |
| Galecto, Inc. | 35.62 Million USD | -2088.192% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -1815.965% |
| Fortrea Holdings Inc. | 457.3 Million USD | -70.476% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1336.285% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -2599.588% |
| XBiotech Inc. | 37.51 Million USD | -1978.344% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1032.117% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -3675.423% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -448.769% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -686.866% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -604.132% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 18.645% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -2602.676% |
| Vaxxinity, Inc. | 56.05 Million USD | -1290.853% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -81.03% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -3394.603% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -603.173% |
| NexImmune, Inc. | 28.16 Million USD | -2667.682% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -13994.998% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -4257.058% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 72.309% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -2962.127% |
| Scopus BioPharma Inc. | 11.71 Million USD | -6554.675% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -513.549% |
| Ainos, Inc. | 12.95 Million USD | -5918.739% |
| Pluri Inc. | 22.48 Million USD | -3367.914% |
| Prothena Corporation plc | 282.4 Million USD | -176.052% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -289.751% |
| Celularity Inc. | 215.05 Million USD | -262.501% |
| Rallybio Corporation | 78.93 Million USD | -887.669% |
| Cue Biopharma, Inc. | 19.54 Million USD | -3889.29% |
| MeiraGTx Holdings plc | 151.07 Million USD | -416.016% |
| Omeros Corporation | 94.75 Million USD | -722.774% |
| Humacyte, Inc. | 23.49 Million USD | -3217.815% |
| Immunocore Holdings plc | 308.04 Million USD | -153.08% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -22896.667% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -797.47% |
| Blueprint Medicines Corporation | 722.86 Million USD | -7.847% |
| CalciMedica, Inc. | 21.81 Million USD | -3473.301% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -944.183% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -385.603% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -355.114% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -164.321% |
| Pulmatrix, Inc. | 22.03 Million USD | -3437.467% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2154.771% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -777.261% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -41.341% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -974.537% |
| Cytokinetics, Incorporated | 173.61 Million USD | -349.04% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2164.99% |
| Nutriband Inc. | 5.73 Million USD | -13495.793% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1687.511% |
| Vor Biopharma Inc. | 126.03 Million USD | -518.543% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 34.443% |
| Evogene Ltd. | 27.79 Million USD | -2705.279% |
| ProKidney Corp. | 151.52 Million USD | -414.504% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -951.01% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -10034.718% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -26.922% |
| CorMedix Inc. | 48.95 Million USD | -1492.366% |
| BioLineRx Ltd. | 50.8 Million USD | -1434.56% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -417.311% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1947.665% |
| Atai Life Sciences N.V. | 125.78 Million USD | -519.777% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -854.916% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -857.618% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -208.684% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2281.145% |
| MediciNova, Inc. | 10.9 Million USD | -7052.0% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -505.175% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10638.817% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12845.277% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -63.655% |
| Biomea Fusion, Inc. | 126.13 Million USD | -518.058% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 40.573% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2075.066% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -307.971% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -239.019% |
| Absci Corporation | 73.66 Million USD | -958.272% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2726.434% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -483.567% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -221.928% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -197.498% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -274.812% |
| Allakos Inc. | 196.05 Million USD | -297.635% |
| Imunon, Inc. | 20.31 Million USD | -3738.359% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -587.048% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -111.493% |
| BioAtla, Inc. | 129.68 Million USD | -501.13% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6502.717% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -4820.703% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -818.047% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -1766.917% |
| XOMA Corporation | 46.46 Million USD | -1577.866% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -601.25% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -447.221% |
| aTyr Pharma, Inc. | 12.97 Million USD | -5906.526% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -652.091% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -350.967% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -206.004% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1984.011% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -9378.476% |
| Akari Therapeutics, Plc | 16.8 Million USD | -4538.742% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -34183.082% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -160.454% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11485.946% |
| UroGen Pharma Ltd. | 138.88 Million USD | -461.306% |
| Sutro Biopharma, Inc. | 243 Million USD | -220.806% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -10616.529% |
| Orgenesis Inc. | 45.75 Million USD | -1603.755% |
| Entera Bio Ltd. | 8.86 Million USD | -8698.95% |
| GH Research PLC | 41.22 Million USD | -1791.192% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -2932.468% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -838.662% |
| Xencor, Inc. | 306.97 Million USD | -153.956% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -15701.566% |
| Replimune Group, Inc. | 234.77 Million USD | -232.06% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -3704.74% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -306.467% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11485.946% |
| Portage Biotech Inc. | 18.19 Million USD | -4183.68% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10638.817% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -642.74% |
| OncoCyte Corporation | 25.63 Million USD | -2940.867% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -12689.325% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -6704.424% |
| Purple Biotech Ltd. | -22.46 Million USD | 3569.92% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -4630.504% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1096.089% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -9122.895% |
| HilleVax, Inc. | 133.34 Million USD | -484.639% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -7479.844% |
| Tharimmune, Inc. | 9.45 Million USD | -8145.043% |
| Genprex, Inc. | 31.06 Million USD | -2409.893% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -315.722% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2384.581% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -101806.797% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -14212.44% |
| OKYO Pharma Limited | 8243.57 USD | -9456810.052% |
| Savara Inc. | 15.74 Million USD | -4851.331% |
| Curis, Inc. | 58.35 Million USD | -1235.939% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2219.55% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -15208.568% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -10348.827% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -2785.009% |
| BeiGene, Ltd. | 3.28 Billion USD | 76.28% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -3809.801% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -56.303% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -407.372% |
| Erasca, Inc. | 141.52 Million USD | -450.848% |
| bluebird bio, Inc. | 240.23 Million USD | -224.514% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -17120.929% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 55.357% |
| DBV Technologies S.A. | 92.16 Million USD | -745.906% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -17120.929% |
| Moderna, Inc. | 6.39 Billion USD | 87.808% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1729.63% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -5326.611% |
| Molecular Templates, Inc. | 63.09 Million USD | -1135.655% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1068.779% |
| Travere Therapeutics, Inc. | 472 Million USD | -65.166% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -443.983% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1155.738% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1695.704% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -274.567% |
| MacroGenics, Inc. | 217.21 Million USD | -258.901% |
| RenovoRx, Inc. | 11.39 Million USD | -6740.883% |
| Adicet Bio, Inc. | 152.03 Million USD | -412.758% |
| Prime Medicine, Inc. | 186.63 Million USD | -317.698% |
| Aditxt, Inc. | 25.95 Million USD | -2904.1% |
| Adagene Inc. | 41.83 Million USD | -1763.643% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10564.522% |
| Quantum-Si incorporated | 111.65 Million USD | -598.186% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -353.644% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -5247.78% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2076.28% |
| SciSparc Ltd. | 9.01 Million USD | -8551.504% |
| Vericel Corporation | 142.04 Million USD | -448.85% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8905.628% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -3276.503% |
| Generation Bio Co. | 144.46 Million USD | -439.63% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -838.922% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -801.674% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -163.623% |
| Invivyd, Inc. | 205.75 Million USD | -278.891% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -980.374% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -8212.488% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -935.941% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -7478.371% |
| 2seventy bio, Inc. | 289.88 Million USD | -168.928% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1070.797% |
| Clene Inc. | 41.07 Million USD | -1798.052% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -5986.773% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1322.708% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12845.277% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -121.443% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2022.364% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2211.394% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -651.757% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2292.178% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -357.832% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -1.546% |
| Evaxion Biotech A/S | 22.27 Million USD | -3400.615% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -475.154% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -231.906% |
| Trevena, Inc. | 38.41 Million USD | -1929.487% |
| Surrozen, Inc. | 18.55 Million USD | -4102.625% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -875.154% |
| Cingulate Inc. | 22.75 Million USD | -3325.372% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 10505.593% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1645.331% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -9367.969% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -660.143% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -3.382% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1155.899% |
| Clearmind Medicine Inc. | 8.74 Million USD | -8818.382% |
| Kronos Bio, Inc. | 128.11 Million USD | -508.491% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -827.285% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -26479.986% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -673.193% |
| Statera Biopharma, Inc. | 28.82 Million USD | -2604.129% |
| ImmunityBio, Inc. | 362.87 Million USD | -114.838% |
| Korro Bio, Inc. | 84.53 Million USD | -822.217% |
| Kineta, Inc. | 21.15 Million USD | -3584.945% |
| BioVie Inc. | 31.95 Million USD | -2340.006% |
| Codexis, Inc. | 66.51 Million USD | -1071.994% |
| Celularity Inc. | 215.05 Million USD | -262.501% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -244.005% |
| Celcuity Inc. | 66.23 Million USD | -1077.085% |
| Virax Biolabs Group Limited | 6.54 Million USD | -11807.431% |
| Cibus, Inc. | 320.3 Million USD | -143.389% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1712.993% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2203.472% |
| IN8bio, Inc. | 30.33 Million USD | -2469.756% |
| Kodiak Sciences Inc. | 277.32 Million USD | -181.114% |
| Annexon, Inc. | 143.72 Million USD | -442.423% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -511.005% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -3302.973% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -121710.469% |
| Eyenovia, Inc. | 25.4 Million USD | -2968.461% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -455.598% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13916.307% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -885.16% |
| Arcellx, Inc. | 200.19 Million USD | -289.406% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1598.447% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -260.234% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -7729.537% |
| Moolec Science SA | 52.75 Million USD | -1377.873% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1175.127% |
| Geron Corporation | 70.44 Million USD | -1006.723% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1575.09% |
| Royalty Pharma plc | 862.4 Million USD | 9.603% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -728.713% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -8257.614% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -3345.15% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -275.141% |
| Humacyte, Inc. | 23.49 Million USD | -3217.815% |
| Structure Therapeutics Inc. | 102.77 Million USD | -658.538% |
| 89bio, Inc. | 151.2 Million USD | -415.586% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -872.879% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -5261.671% |
| Genelux Corporation | 24.33 Million USD | -3103.563% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2198.107% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -350.97% |
| Notable Labs, Ltd. | 14.77 Million USD | -5178.179% |
| Liquidia Corporation | 87.98 Million USD | -786.055% |
| Mustang Bio, Inc. | 48.5 Million USD | -1507.363% |
| Immunovant, Inc. | 282.7 Million USD | -175.756% |
| Quantum-Si incorporated | 111.65 Million USD | -598.186% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -3358.069% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -3565.712% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -664.211% |
| Acasti Pharma Inc. | 11.3 Million USD | -6798.39% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -3301.175% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4778.712% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1575.018% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -68611.506% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -4807.384% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -2573.756% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -1783.788% |
| PepGen Inc. | 84.76 Million USD | -819.693% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -2530.984% |
| United Therapeutics Corporation | 885.1 Million USD | 11.921% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -3304.756% |
| Solid Biosciences Inc. | 104.31 Million USD | -647.339% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2282.198% |
| Immuneering Corporation | 58.41 Million USD | -1234.615% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15215.341% |
| Silo Pharma, Inc. | 3.92 Million USD | -19778.012% |
| Belite Bio, Inc | 31.66 Million USD | -2361.75% |
| XOMA Corporation | 46.46 Million USD | -1577.866% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1054.089% |
| Bionomics Limited | 17.89 Billion USD | 95.643% |
| Apogee Therapeutics, Inc. | 93 Million USD | -738.239% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2284.941% |
| uniQure N.V. | 285.08 Million USD | -173.457% |
| Cassava Sciences, Inc. | 105.95 Million USD | -635.758% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10564.522% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -301.421% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2300.428% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -9282.717% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -2552.108% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13916.307% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5386.186% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -8670.244% |
| Altimmune, Inc. | 30.55 Million USD | -2451.339% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -82.295% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2284.941% |
| Compugen Ltd. | 43.97 Million USD | -1672.957% |
| Peak Bio, Inc. | 1249.13 USD | -62410297.637% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -951.79% |
| Benitec Biopharma Inc. | 22.38 Million USD | -3383.098% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -220.568% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -2631.272% |
| Zura Bio Limited | 62.63 Million USD | -1144.591% |
| PolyPid Ltd. | 21.04 Million USD | -3604.381% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -4689.795% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -2631.272% |
| Instil Bio, Inc. | 85.78 Million USD | -808.768% |
| argenx SE | 1.53 Billion USD | 49.164% |
| Immunome, Inc. | 122.82 Million USD | -534.739% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1508.291% |
| Verona Pharma plc | 67.15 Million USD | -1060.941% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -2911.733% |
| Shattuck Labs, Inc. | 93.61 Million USD | -732.768% |
| CervoMed Inc. | 14.95 Million USD | -5111.921% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1002.622% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -9024.38% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1428.602% |
| Moolec Science SA | 52.75 Million USD | -1377.873% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -4639.58% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -488.123% |
| AnaptysBio, Inc. | 181.56 Million USD | -329.364% |
| Design Therapeutics, Inc. | 78.19 Million USD | -897.042% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -795.655% |
| NeurAxis, Inc. | 8.82 Million USD | -8737.653% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -6094.573% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1916.26% |
| Achilles Therapeutics plc | 75.25 Million USD | -935.927% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -2911.733% |
| 180 Life Sciences Corp. | 13.47 Million USD | -5684.359% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -2841.567% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -26479.986% |
| Nutriband Inc. | 5.73 Million USD | -13495.793% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -603.725% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1300.8% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1432.237% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1079.423% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1340.396% |
| Palisade Bio, Inc. | 13.32 Million USD | -5752.755% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1616.812% |
| Beam Therapeutics Inc. | 554.19 Million USD | -40.67% |
| Neurogene Inc. | 55.58 Million USD | -1302.564% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -213.731% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1509.752% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -706.108% |
| Sesen Bio, Inc. | 78.38 Million USD | -894.612% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -833.313% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -6093.64% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -72.86% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -787.003% |
| Athira Pharma, Inc. | 125.46 Million USD | -521.353% |
| Vaccinex, Inc. | 23.45 Million USD | -3223.756% |
| HCW Biologics Inc. | 21.02 Million USD | -3607.461% |
| XOMA Corporation | 46.46 Million USD | -1577.866% |
| Nektar Therapeutics | 190.9 Million USD | -308.368% |
| Arvinas, Inc. | 480 Million USD | -62.414% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -34183.082% |
| Merus N.V. | 200.49 Million USD | -288.833% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -654.281% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2151.84% |
| Rezolute, Inc. | 70.38 Million USD | -1007.572% |
| Clene Inc. | 41.07 Million USD | -1798.052% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -4659.827% |
| BeyondSpring Inc. | 24.86 Million USD | -3035.279% |
| Synlogic, Inc. | 58.53 Million USD | -1231.899% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -4257.182% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -17255.009% |
| Peak Bio, Inc. | 1249.13 USD | -62410297.637% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1189.725% |
| Krystal Biotech, Inc. | 160.42 Million USD | -385.948% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -188.063% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -123.995% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -36046.646% |
| MannKind Corporation | 125.59 Million USD | -520.705% |
| Ikena Oncology, Inc. | 84.57 Million USD | -821.748% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -7981.134% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -770.065% |
| Gossamer Bio, Inc. | 183.75 Million USD | -324.244% |
| CohBar, Inc. | 12.38 Million USD | -6192.931% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1436.919% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2726.434% |
| Legend Biotech Corporation | 583.14 Million USD | -33.687% |
| Mural Oncology plc | 192.07 Million USD | -305.885% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1061.015% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -4728.578% |
| Disc Medicine, Inc. | 91.12 Million USD | -755.514% |
| Champions Oncology, Inc. | 28.11 Million USD | -2673.344% |
| REGENXBIO Inc. | 321.15 Million USD | -142.743% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -14441.186% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1298.212% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1900.96% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -581.713% |
| Vaxart, Inc. | 90.72 Million USD | -759.276% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -9050.074% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1721.717% |
| Cellectis S.A. | 97.32 Million USD | -701.055% |
| Longeveron Inc. | 21.25 Million USD | -3568.645% |
| Repare Therapeutics Inc. | 167.35 Million USD | -365.823% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 42.712% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -930.586% |
| Revolution Medicines, Inc. | 498.76 Million USD | -56.303% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -11619.588% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1673.643% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -945.163% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1019.533% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -6948.707% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 83.674% |
| Denali Therapeutics Inc. | 527.23 Million USD | -47.865% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8905.628% |
| Veru Inc. | 101.34 Million USD | -669.217% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3230.572% |
| Cingulate Inc. | 22.75 Million USD | -3325.372% |
| Passage Bio, Inc. | 108.38 Million USD | -619.249% |
| Context Therapeutics Inc. | 25.07 Million USD | -3009.317% |
| Exicure, Inc. | 14.07 Million USD | -5438.413% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -278.323% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1700.39% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -8394.741% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -208.768% |
| Nuvalent, Inc. | 149.49 Million USD | -421.491% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -9564.02% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -652.134% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -3534.608% |
| OmniAb, Inc. | 83.89 Million USD | -829.241% |
| Anew Medical, Inc. | 1.3 Million USD | -59829.461% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2279.401% |
| Lipocine Inc. | 15.08 Million USD | -5069.627% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1037.867% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -923.725% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1833.772% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -578.828% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -3382.787% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -17.382% |
| Ocugen, Inc. | 71.56 Million USD | -989.311% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -730.532% |
| Q32 Bio Inc. | 92.68 Million USD | -741.16% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -3581.813% |
| Alumis Inc. Common Stock | 158.17 Million USD | -392.867% |
| Equillium, Inc. | 50.6 Million USD | -1440.503% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1149.218% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -5506.299% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -4032.428% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1560.427% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -618.739% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -6190.682% |
| Dominari Holdings Inc. | 23.83 Million USD | -3170.766% |
| Edesa Biotech, Inc. | 9.22 Million USD | -8352.862% |
| vTv Therapeutics Inc. | 11.9 Million USD | -6447.3% |
| Bio-Techne Corporation | 563.03 Million USD | -38.461% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -90.699% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -190.072% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -489.359% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -5309.666% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -376.241% |
| Nkarta, Inc. | 131.65 Million USD | -492.166% |
| BioCardia, Inc. | 12.12 Million USD | -6331.705% |
| Iterum Therapeutics plc | 47.46 Million USD | -1542.342% |